Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Organogenesis Holdings Inc. - Class A
(NQ:
ORGO
)
3.920
-0.080 (-2.00%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organogenesis Holdings Inc. - Class A
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 13, 2021
Gainers Itamar Medical (NASDAQ:ITMR) shares increased by 46.58% to $30.25 during Monday's regular session. Trading volume for Itamar Medical's stock is 2.6 million...
Via
Benzinga
Organogenesis Q2 Earnings Beat Expectations; Sales Jump 79%; Raises FY21 Sales Outlook
↗
August 10, 2021
Organogenesis Holdings Inc (NASDAQ: ORGO) Q2 revenues increased 79% Y/Y to $123.2 million, edging out analysts' average expectation of $107.30 million. The increase...
Via
Benzinga
Topics
Earnings
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
August 10, 2021
Gainers Arcturus Therapeutics (NASDAQ:ARCT) shares rose 25.93% to $60.75 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.5...
Via
Benzinga
Organogenesis Holdings Inc (ORGO) Q2 2021 Earnings Call Transcript
↗
August 10, 2021
ORGO earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Organogenesis Holdings: Q2 Earnings Insights
↗
August 09, 2021
Shares of Organogenesis Holdings (NASDAQ:ORGO) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 400.00% year over...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
↗
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Earnings Scheduled For May 10, 2021
↗
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
Stocks That Hit 52-Week Highs On Friday
↗
April 09, 2021
During the morning session on Friday, 178 stocks hit new 52-week highs. Noteworthy Points: Microsoft (NASDAQ:MSFT) was the largest firm on a market cap basis to set...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
↗
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Earnings Scheduled For August 9, 2021
↗
August 09, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •...
Via
Benzinga
Organogenesis Holdings Insights: Return On Capital Employed
↗
June 24, 2021
Organogenesis Holdings (NASDAQ:ORGO) posted Q1 earnings of $12.62 million, an increase from Q4 of 42.05%. Sales dropped to $102.55 million, a 3.98% decrease between quarters. In...
Via
Benzinga
Looking Into Organogenesis Holdings's Return On Capital Employed
↗
June 08, 2021
Looking at Q1, Organogenesis Holdings (NASDAQ:ORGO) earned $12.62 million, a 42.05% increase from the preceding quarter. Organogenesis Holdings's sales decreased to $102.55...
Via
Benzinga
3 Biotech Stocks Wall Street Predicts Will Rally By 45% Or More
↗
May 30, 2021
Wall Street analysts expect the biotech industry to grow significantly soon, with the biotech stocks Organogenesis (ORGO), BioDelivery Sciences (BDSI) and Champions Oncology (CSBR) gaining more...
Via
Talk Markets
Why Organogenesis Holdings Blasted 7.7% Higher Today
↗
May 27, 2021
The company will be a component of a high-profile stock index.
Via
The Motley Fool
Topics
Stocks
41 Stocks Moving In Thursday's Mid-Day Session
↗
May 27, 2021
Gainers 1847 Goedeker Inc. (NYSE: GOED) shares jumped 156.5% to $11.08 after dropping over 8% on Wednesday. Vertex Energy, Inc. (NASDAQ: VTNR) jumped 117% to $3.8604 after the...
Via
Benzinga
60 Biggest Movers From Yesterday
↗
May 28, 2021
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) shares climbed 124.2% to settle at $3.99 on Thursday after the company announced plans to acquire a Alabama refinery and related...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 27, 2021
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The company's market cap stands at $97.3 million....
Via
Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
↗
May 27, 2021
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets....
Via
Benzinga
Organogenesis Holdings Inc (ORGO) Q1 2021 Earnings Call Transcript
↗
May 11, 2021
ORGO earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Organogenesis Holdings: Q1 Earnings Insights
↗
May 10, 2021
Shares of Organogenesis Holdings (NASDAQ:ORGO) increased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 143.75% year over...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
May 10, 2021
Gainers Vir Biotechnology (NASDAQ:VIR) sha...
Via
Benzinga
Earnings Outlook for Organogenesis Holdings
↗
May 07, 2021
Organogenesis Holdings (NASDAQ:ORGO) releases its next round of earnings this Monday, May 10. Here is Benzinga's essential guide to Organogenesis Holdings's Q1 earnings report....
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
↗
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 04, 2021
Gainers Obalon Therapeutics (NASDAQ:OBLN)...
Via
Benzinga
Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due
↗
April 28, 2021
A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86
↗
April 27, 2021
On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 26, 2021
Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) shares rose 72.91% to $7.47 during Monday's regular session. Reviva Pharmaceuticals's stock is trading at a volume of...
Via
Benzinga
Align Technology Nears Buy Point With Earnings Due
↗
April 21, 2021
Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28.
Via
Investor's Business Daily
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
↗
April 21, 2021
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member.
Via
Investor's Business Daily
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
↗
April 14, 2021
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.